Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Pharmaceutical Congress of São Paulo. Unidade: FCF
Subjects: STAPHYLOCOCCUS, FARMACOCINÉTICA, FARMACODINÂMICA
ABNT
SILVA, Vedilaine Aparecida Bueno da et al. Is vancomycin therapeutic target against Staphylococcus SPP MIC1mg/L achieved after the empirical dose regimen recommended to critically septic pediatrics?. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 14 nov. 2024. , 2017APA
Silva, V. A. B. da, Silva Júnior, J. M. da, Campos, E. V. de, Silva Junior, C. V. da, Gomez, D. de S., & Santos, S. R. C. J. (2017). Is vancomycin therapeutic target against Staphylococcus SPP MIC1mg/L achieved after the empirical dose regimen recommended to critically septic pediatrics? Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.NLM
Silva VAB da, Silva Júnior JM da, Campos EV de, Silva Junior CV da, Gomez D de S, Santos SRCJ. Is vancomycin therapeutic target against Staphylococcus SPP MIC1mg/L achieved after the empirical dose regimen recommended to critically septic pediatrics? Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 113 res. CFSP209.[citado 2024 nov. 14 ]Vancouver
Silva VAB da, Silva Júnior JM da, Campos EV de, Silva Junior CV da, Gomez D de S, Santos SRCJ. Is vancomycin therapeutic target against Staphylococcus SPP MIC1mg/L achieved after the empirical dose regimen recommended to critically septic pediatrics? Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 113 res. CFSP209.[citado 2024 nov. 14 ]